Krystal Biotech (KRYS)
$
9
8
7
6
5
4
3
2
1
0
9
8
7
6
5
4
3
2
1
0
9
8
7
6
5
4
3
2
1
0
9
8
7
6
5
4
3
2
1
0
9
8
7
6
5
4
3
2
1
0
9
8
7
6
5
4
3
2
1
0
9
8
7
6
5
4
3
2
1
0
9
8
7
6
5
4
3
2
1
0
About
Business overview of Krystal Biotech (KRYS)
Krystal Biotech Inc is engaged in the healthcare sector in the United States. It is focused on the development of easy-to-use, redosable gene therapies to improve the lives of patients living with debilitating diseases. The company used its proprietary gene therapy platform, STAR-D to develop treatments for rare or orphan dermatological indications caused by the absence of or a mutation in a single gene. It plans to leverage its platform to expand its pipeline to include other dermatological indications in the future. The company has one operating segment, which is the business of developing and commercializing pharmaceutical products.
Key Insights
Critical company metrics and information
Share Price
$190.00Market Cap
$5.46 BillionTotal Outstanding Shares
28.76 Million SharesTotal Employees
229Dividend
No dividendIPO Date
September 20, 2017SIC Description
Biological Products, (no Disgnostic Substances)Homepage
https://www.krystalbio.com
Historical Stock Splits
Execution Date | Split Amount |
---|---|
No Historical Stock Splits |
Cash Flow Statement
October 1, 2023 to September 30, 2024
Metric | Value |
---|---|
Net Cash Flow, Continuing | $729000.00 |
Exchange Gains/Losses | $4000.00 |
Net Cash Flow | $725000.00 |
Net Cash Flow From Operating Activities | $63.34 Million |
Net Cash Flow From Investing Activities | $-89.82 Million |
Net Cash Flow From Investing Activities, Continuing | $-89.82 Million |
Net Cash Flow From Financing Activities | $27.20 Million |
Net Cash Flow From Operating Activities, Continuing | $63.34 Million |
Net Cash Flow From Financing Activities, Continuing | $27.20 Million |
Income Statement
October 1, 2023 to September 30, 2024
Metric | Value |
---|---|
Net Income/Loss Attributable To Parent | $52.37 Million |
Research and Development | $51.42 Million |
Income Tax Expense/Benefit | $5.03 Million |
Operating Expenses | $214.06 Million |
Income/Loss From Continuing Operations After Tax | $52.37 Million |
Diluted Earnings Per Share | $1.78 |
Participating Securities, Distributed And Undistributed Earnings/Loss, Basic | $0.00 |
Costs And Expenses | $184.12 Million |
Benefits Costs and Expenses | $184.12 Million |
Net Income/Loss Available To Common Stockholders, Basic | $52.37 Million |
Operating Income/Loss | $27.45 Million |
Other Operating Expenses | $153.88 Million |
Basic Average Shares | $85.95 Million |
Net Income/Loss Attributable To Noncontrolling Interest | $0.00 |
Basic Earnings Per Share | $1.84 |
Income/Loss From Continuing Operations Before Tax | $57.40 Million |
Net Income/Loss | $52.37 Million |
Preferred Stock Dividends And Other Adjustments | $0.00 |
Revenues | $241.52 Million |
Diluted Average Shares | $89.20 Million |
Balance Sheet
October 1, 2023 to September 30, 2024
Metric | Value |
---|---|
Equity Attributable To Noncontrolling Interest | $0.00 |
Inventory | $18.58 Million |
Other Current Liabilities | $83.95 Million |
Equity Attributable To Parent | $885.85 Million |
Current Liabilities | $89.53 Million |
Cash | $588.30 Million |
Current Assets | $713.16 Million |
Liabilities | $96.47 Million |
Other Non-current Assets | $112.56 Million |
Other Current Assets | $106.28 Million |
Accounts Payable | $5.58 Million |
Noncurrent Assets | $269.15 Million |
Noncurrent Liabilities | $6.95 Million |
Fixed Assets | $156.59 Million |
Liabilities And Equity | $982.32 Million |
Equity | $885.85 Million |
Assets | $982.32 Million |
Historical Dividends
Announcement Date | Payment Date | Record Date | Amount | Frequency |
---|---|---|---|---|
No historical dividends |
Boost your savings and earn 4.35% APY with a Marcus by Goldman Sachs savings account, a rate that's 8x the national averagewhen signing up with Financhle. No fees, no minimum deposits, backed by the financial expertise of Goldman Sachs. Terms apply.
â“’ 2024 Financhle. All Rights Reserved.